Header Logo

Connection

RAJKUMAR VENKATRAMANI to Neoplasm Recurrence, Local

Back to Details
This is a "connection" page, showing publications RAJKUMAR VENKATRAMANI has written about Neoplasm Recurrence, Local.
RAJKUMAR VENKATRAMANI
Connection Strength
2.083
Neoplasm Recurrence, Local
  1. Outcomes of relapsed favorable-histology Wilms tumor in non-clinical trial setting. Pediatr Blood Cancer. 2025 Jan; 72(1):e31347.
    View in: PubMed
    Score: 0.268
  2. Alpha-emitter therapy for pediatric relapsed metastatic pancreatic neuroendocrine tumor. Pediatr Blood Cancer. 2024 Jun; 71(6):e30961.
    View in: PubMed
    Score: 0.258
  3. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis. J Pediatr Hematol Oncol. 2021 03 01; 43(2):e215-e218.
    View in: PubMed
    Score: 0.209
  4. Salvage regimens for pediatric patients with relapsed nasopharyngeal carcinoma. Pediatr Blood Cancer. 2019 01; 66(1):e27469.
    View in: PubMed
    Score: 0.177
  5. Gemcitabine-induced radiation recall myositis in a patient with relapsed nasopharyngeal carcinoma. Pract Radiat Oncol. 2017 Jan - Feb; 7(1):e19-e22.
    View in: PubMed
    Score: 0.150
  6. Successful treatment of recurrent metastatic nasopharyngeal carcinoma with oxaliplatin and doxorubicin. J Pediatr Hematol Oncol. 2014 Jul; 36(5):e307-9.
    View in: PubMed
    Score: 0.131
  7. Hepatoblastoma in children with Beckwith-Wiedemann syndrome: does it warrant different treatment? J Pediatr Hematol Oncol. 2014 Jul; 36(5):369-73.
    View in: PubMed
    Score: 0.131
  8. Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab. Pediatr Blood Cancer. 2014 Apr; 61(4):756-9.
    View in: PubMed
    Score: 0.125
  9. A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors. Pediatr Blood Cancer. 2013 Jul; 60(7):1103-7.
    View in: PubMed
    Score: 0.119
  10. Event-free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2024 Jul; 71(7):e31009.
    View in: PubMed
    Score: 0.065
  11. Outcome of patients with relapsed or refractory nonrhabdomyosarcoma soft tissue sarcomas enrolled in phase 2 cooperative group clinical trials: A report from the Children's Oncology Group. Cancer. 2024 Jul 15; 130(14):2493-2502.
    View in: PubMed
    Score: 0.064
  12. Soft Tissue and Visceral Organ Sarcomas With BCOR Alterations. J Pediatr Hematol Oncol. 2022 07 01; 44(5):195-200.
    View in: PubMed
    Score: 0.057
  13. Borderline Ovarian Tumor in the Pediatric and Adolescent Population: A Case Series and Literature Review. J Pediatr Adolesc Gynecol. 2018 Feb; 31(1):48-54.
    View in: PubMed
    Score: 0.041
  14. Juvenile Granulosa Cell Tumor of the Ovary: A Clinicopathologic Study. J Pediatr Adolesc Gynecol. 2017 Feb; 30(1):138-143.
    View in: PubMed
    Score: 0.038
  15. Refractory Kaposiform Hemangioendothelioma Associated with the Chromosomal Translocation t(13;16)(q14;p13.3). Pediatr Dev Pathol. 2016 Sep/Oct; 19(5):417-420.
    View in: PubMed
    Score: 0.036
  16. Zoledronic Acid for the Treatment of Children With Refractory Central Giant Cell Granuloma. J Pediatr Hematol Oncol. 2015 Aug; 37(6):e399-401.
    View in: PubMed
    Score: 0.035
  17. Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma. Pediatr Hematol Oncol. 2015 Feb; 32(1):26-31.
    View in: PubMed
    Score: 0.034
  18. Current and future management strategies for relapsed or progressive hepatoblastoma. Paediatr Drugs. 2012 Aug 01; 14(4):221-32.
    View in: PubMed
    Score: 0.029
  19. Late Events Occurring After 5?Years in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2025 Jan; 72(1):e31421.
    View in: PubMed
    Score: 0.017
  20. The impact of margins and re-resection in pediatric synovial sarcoma. Cancer Med. 2024 Sep; 13(17):e70207.
    View in: PubMed
    Score: 0.017
  21. Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis. Cancer Med. 2023 05; 12(9):10222-10229.
    View in: PubMed
    Score: 0.015
  22. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. Eur J Cancer. 2022 09; 172:367-386.
    View in: PubMed
    Score: 0.014
  23. Congenital spindle cell rhabdomyosarcoma: An international cooperative analysis. Eur J Cancer. 2022 06; 168:56-64.
    View in: PubMed
    Score: 0.014
  24. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)?. ESMO Open. 2021 10; 6(5):100250.
    View in: PubMed
    Score: 0.014
  25. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. Lancet Oncol. 2021 09; 22(9):1312-1321.
    View in: PubMed
    Score: 0.013
  26. Multimodal molecular analysis of an atypical small cell carcinoma of the ovary, hypercalcemic type. Cold Spring Harb Mol Case Stud. 2018 10; 4(5).
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.